Advanced diagnostics for cancer represent a major market opportunity for life sciences companies. Many cancer types are on the rise as the aging populations of many countries continue to grow. As a result, there is an increasing demand for noninvasive, diagnostic assays that can detect cancers earlier, molecularly subtype tumors to guide therapy decisions and monitor cancer recurrence in treated individuals.
Despite advances in treatment, cancer remains the second leading cause of death, worldwide. Cancer exerts a tremendous toll on patients, families and society as a whole. One pressing need in cancer diagnostics is earlier stage identification, identifying cancer before it has spread to other parts of body. In order to meet this need, a number of companies are using advanced diagnostic platforms to develop and validate assays that detect cancer earlier. Sanomics, Prenetics, Guardant, Thrive Earlier Detection, AnPac BioMedical and Grail are notable examples.
A second pressing need in cancer is more accurate classification of suspicious lesions or nodules (malignant or benign). Accurate classification leads to better treatment decisions and fewer unnecessary, invasive biopsies. In the case of lung cancer, peripheral lung nodules are very difficult to biopsy, deep within the small branches of the lung, often beyond the reach of the bronchoscope. Needle biopsy is problematic, carrying the risk of lung collapse and/or infection. New, non-invasive blood-based tests are needed to assess nodules.
A third, important medical need is for cancer diagnostics that guide therapy decisions. These diagnostics can be used to assess a patient’s likely response to a particular therapy, providing the physician with a guide to subsequent treatments. This is a growing application for both tissue and liquid-based assays.
These assays establish which of the newer, targeted drugs, including those that block certain molecular pathways, will work most effectively for a given tumor. This convergence of targeted drugs with genomics-based diagnostics leads to a powerful new paradigm in medicine.
The scope of this report includes next generation diagnostic technologies, applications, industry subsegments, major funding initiatives, patents and companies. The market sizes for next generation cancer diagnostics are given for 2019, 2020 (estimated) and 2025 (forecasted).
This report reviews the main next generation diagnostic technologies, including next generation sequencing (NGS), polymerase chain reaction (PCR), multiplex conventional, cell or extracellular vesicle capture and arrays/microfluidics. The report also discusses, in-depth, various liquid biopsy platforms and how these compare with tissue-based testing.
The report discusses several significant, large-scale research initiatives that contribute to cancer diagnostic development. Key forces driving the market are enumerated.
The structures of several important industry subsectors are reviewed, as well as major industry acquisitions and strategic alliances from Jan. 2019 through June 2020. The industry subsectors analyzed include DNA sequencing instruments, long-read DNA sequencing, informatics, PCR, droplet digital PCR, CTC capture and detection and liquid biopsy.
The market for next generation cancer diagnostics is analyzed in depth. The market is analyzed by cancer site (bladder, brain, breast, colorectal, cancer of unknown primary, gastric, gynecologic, hematologic, kidney, liver, lung, pan-cancer, pancreatic, prostate, melanoma and thyroid), by test purpose (screening/early detection, diagnosis, monitoring, therapy guidance), by test platform (arrays/microfluidics, cell/EV capture, multiplex conventional, PCR and NGS) and by geography (North America, Europe, Asia Pacific, Rest of World).
Market data covers 2019, 2020 (estimated) and 2025 (forecasted).
There is a special section discussing the impact of COVID-19 on the market for next generation cancer diagnostics.
More than 130 companies in the next generation cancer diagnostics industry are profiled in this report.
Report provides a summary of the main industry acquisitions and strategic alliances from Jan. 2019 through June 2020, including key alliance trends.
– 22 data tables and 74 additional tables
– An overview of the global market and technologies for next generation cancer diagnostics
– Analyses of global market trends, with data from 2019, estimates for 2020, and projections of compound annual growth rates (CAGRs) through 2025
– Analyses of the next generation cancer diagnostics market by cancer site, analysis purpose, analysis platform and region
– Discussion on arrays and microfluidics (LOAC) technologies, multiplex conventional technologies, next generation sequencing technology and polymerase chain reaction (PCR) technology
– Evaluation of current market trends, market size, market forecast, pipeline analysis of new products, and regulatory scenarios of the cancer diagnostics market
– Discussion on factors affecting the market including cancer diagnostics needs, regulatory trends, industry structure, and patent statuses
– Details of the key initiatives and programs related to the next generation cancer diagnostics market
– Market share analysis of the key companies of the industry, their strategic profiling, competitive landscape, and their detailed company profiles, including Abbott Laboratories, Illumina Inc., Myriad Genetics Inc., Qiagen NV, Oche Holding AG, and Thermo Fisher Scientific Inc.20/20 GENE SYSTEMS
ADAPTIVE BIOTECHNOLOGIES INC.
AGILENT TECHNOLOGIES INC.
AKADEUM LIFE SCIENCES
AMOY DIAGNOSTICS CO. LTD.
Arbor Vita Corp.
BECTON, DICKINSON AND CO.
BIOLOGICAL DYNAMICS INC.
BLUESTAR GENOMICS INC.
CANCER GENETICS INC.
CARIS LIFE SCIENCES
CASTLE BIOSCIENCES INC.
Cc Diagnostics Bv
CELL MICROSYSTEMS INC.
CLINICAL GENOMICS TECHNOLOGIES
EPIC SCIENCES INC.
EXACT SCIENCES CORP.
FLUXION BIOSCIENCES INC.
Fulgent Genetics Inc.
GENESEQ BIOSCIENCES PTY LTD.
Genetron Health Technologies Inc.
GENEXOSOME TECHNOLOGIES INC.
GUARDANT HEALTH INC.
HTG MOLECULAR DIAGNOSTICS INC.
Interpace Biosciences Inc.
JBS SCIENCE INC.
LABORATORY CORP. OF AMERICA INC.
LEXENT BIO INC.
LUCENCE DIAGNOSTICS PTE. LTD.
LUNGLIFE AI, INC.
MDNA LIFE SCIENCES INC.
MENARINI SILICON BIOSYSTEMS SPA
My Personal Therapeutics Ltd.
MYRIAD GENETICS INC.
Neo New Oncology Gmbh
Oncimmune Holdings Plc
OXFORD GENE TECHNOLOGY
Pacific Edge Ltd.
PERSONAL GENOME DIAGNOSTICS INC.
PROVISTA DIAGNOSTICS INC.
QUEST DIAGNOSTICS INC.
RESOLUTION BIOSCIENCE INC.
ROCHE HOLDING AG
Saga Diagnostics Ab
Sienna Cancer Diagnostics Ltd.
SINGLERA GENOMICS INC.
Stage Zero Life Sciences
STRAND LIFE SCIENCES PVT., LTD.
SYSMEX INOSTICS GMBH
THERMO FISHER SCIENTIFIC INC.
Thrive Earlier Detection Corp.
Tiziana Life Sciences Plc
XING TECHNOLOGIES LLC
YIKON GENOMICS CO. LTD.
Table of Contents
Chapter 1 Introduction
Chapter 2 Summary and Highlights
Chapter 3 Overview
Chapter 4 Technologies
Chapter 5 Liquid Biopsy Technologies
Chapter 6 Next Generation Cancer Diagnostics: Key Initiatives and Programs
Chapter 7 Next Generation Cancer Diagnostic Applications by Cancer Site
Chapter 8 Cancer Diagnostics Industries
Chapter 9 Industry Acquisitions and Strategic Alliances
Chapter 10 Cancer Diagnostics Markets
Chapter 11 Patents
Chapter 12 Company Profiles
Read Other Reports from our Database :
Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. We also provide COTS (Commercial off the Shelf) business sector reports as custom exploration agreeing your particular needs.
Ph: +162 825 80070 (US)
Ph: +44 203 500 2763 (UK)